This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. PDL BioPharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2020 was $0.434. PDL BioPharma's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.
As of today (2024-04-25), PDL BioPharma's share price is $2.47. PDL BioPharma's Median PS Value is $0.00. Therefore, PDL BioPharma's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for PDL BioPharma's Median PS Value or its related term are showing as below:
PDLI's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.66 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
PDL BioPharma Median PS Value Historical Data
The historical data trend for PDL BioPharma's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PDL BioPharma's Median PS Value
For the Biotechnology subindustry, PDL BioPharma's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PDL BioPharma's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PDL BioPharma's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where PDL BioPharma's Price-to-Median-PS-Value falls into.
PDL BioPharma Median PS Value Calculation
PDL BioPharma's Median PS Value for today is calculated as
10-Year Median PS Ratio is 0.
PDL BioPharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.434.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PDL BioPharma (NAS:PDLI) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
PDL BioPharma's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
2.47
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PDL BioPharma Median PS Value Related Terms
Thank you for viewing the detailed overview of PDL BioPharma's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
PDL BioPharma (PDL BioPharma) Business Description
PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PDLI has been successfully added to your 